{"disease":{"id":"infections","name":"infections","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":72},"drugs":{"marketed":[{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"zavicefta-ceftazidime-avibactam","indication_name":"Complicated intra-abdominal infections (cIAI) caused by certain susceptible bacteria.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavicefta, Ceftazidime-Avibactam","generic_name":"zavicefta-ceftazidime-avibactam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall synthesis","drug_class":"Cephalosporin antibiotic and beta-lactamase inhibitor combination","quality_score":55,"revenue":"638","mechanism":""},{"drug_id":"cefiderocol","indication_name":"Gram-Negative Bacterial Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fetroja","generic_name":"CEFIDEROCOL","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":"300","mechanism":"Fetroja works by binding to penicillin-binding proteins on bacterial cell walls, inhibiting cell wall synthesis and ultimately leading to bacterial cell death."},{"drug_id":"cefoxitin","indication_name":"Lower respiratory tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Gynecological infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Bone and joint infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin","indication_name":"Skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nystatin","indication_name":"Cutaneous or Mucocutaneous Mycotic Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycostatin","generic_name":"nystatin","company_name":"Generic (originally Squibb)","drug_phase":"marketed","molecular_target":"Ergosterol (fungal cell membrane)","drug_class":"Polyene Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cephalexin","indication_name":"Respiratory tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"cephalexin","indication_name":"Skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"cephalexin","indication_name":"Bone infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"cephalexin","indication_name":"Genitourinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"fluconazole","indication_name":"Candida urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Systemic Candida infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Lower respiratory tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"cefoxitin-sodium","indication_name":"Urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"cefoxitin-sodium","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"cefoxitin-sodium","indication_name":"Gynecological infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"cefoxitin-sodium","indication_name":"Bone and joint infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"cefoxitin-sodium","indication_name":"Skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"sodium-hypochlorite","indication_name":"Prevent and treat skin infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM HYPOCHLORITE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sodium hypochlorite","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"sodium-hypochlorite","indication_name":"Prevent and treat tissue infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM HYPOCHLORITE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sodium hypochlorite","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"sodium-hypochlorite","indication_name":"Pre and post surgery infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SODIUM HYPOCHLORITE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"sodium hypochlorite","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1200962","indication_name":"Uncomplicated and Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"chembl-chembl1200962","indication_name":"Uncomplicated Skin and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"chembl-chembl1200962","indication_name":"Complicated Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFEPIME HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"flucytosine","indication_name":"Serious Candida Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"flucytosine","indication_name":"Candida Pulmonary Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"flucytosine","indication_name":"Cryptococcus Pulmonary Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"flucytosine","indication_name":"Cryptococcus Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ceftazidime","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Skin and Skin-Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"relebactam","indication_name":"Complicated Urinary Tract Infections (cUTI), including Pyelonephritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"relebactam","indication_name":"Complicated Intra-abdominal Infections (cIAI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"ceftazidime","indication_name":"Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Bone and Joint Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Gynecologic Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Central Nervous System Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"posaconazole","indication_name":"Prophylaxis of Invasive Aspergillus and Candida Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"POSACONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"acetic-acid","indication_name":"Superficial external auditory canal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydrocortisone And Acetic Acid","generic_name":"ACETIC ACID","company_name":"Hikma","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"acetic acid","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"voriconazole","indication_name":"Serious fungal infections caused by Scedosporium apiospermum and Fusarium species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"amoxicillin-and-clavulanate","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicillin and clavulanate","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Amoxicillin and Clavulanate Potassium is an antibacterial drug."},{"drug_id":"amoxicillin-and-clavulanate","indication_name":"Skin and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicillin and clavulanate","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Amoxicillin and Clavulanate Potassium is an antibacterial drug."},{"drug_id":"amoxicillin-and-clavulanate","indication_name":"Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicillin and clavulanate","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Amoxicillin and Clavulanate Potassium is an antibacterial drug."},{"drug_id":"voriconazole","indication_name":"Deep Tissue Candida Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"foscarnet","indication_name":"Acyclovir-Resistant Mucocutaneous HSV Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Foscavir","generic_name":"FOSCARNET","company_name":"Clinigen Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrophosphate Analog DNA Polymerase Inhibitor","quality_score":75,"revenue":null,"mechanism":"Foscarnet works by directly inhibiting viral DNA polymerase, preventing the replication of viral DNA."},{"drug_id":"penicillin-g-sodium","indication_name":"Listeria Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENICILLIN G SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"penicillin-g-sodium","indication_name":"Pasteurella Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENICILLIN G SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"penicillin-g-sodium","indication_name":"Disseminated Gonococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENICILLIN G SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"penicillin-g-sodium","indication_name":"Gram-Negative Bacillary Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PENICILLIN G SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"ampicillin-sodium","indication_name":"Skin and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AMPICILLIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"ampicillin-sodium","indication_name":"Intra-Abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AMPICILLIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"ampicillin-sodium","indication_name":"Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AMPICILLIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"delafloxacin","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baxdela","generic_name":"DELAFLOXACIN","company_name":"Melinta","drug_phase":"marketed","molecular_target":"","drug_class":"Fluoroquinolone Antibacterial","quality_score":65,"revenue":null,"mechanism":"Baxdela works by blocking bacterial enzymes that replicate DNA."},{"drug_id":"colistimethate","indication_name":"Acute or Chronic Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COLISTIMETHATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"colistimethate","indication_name":"Infections Due to Pseudomonas aeruginosa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COLISTIMETHATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"colistimethate","indication_name":"Infections Due to Specific Gram-Negative Organisms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COLISTIMETHATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"colistimethate","indication_name":"Serious Infections Suspected to be Due to Gram-Negative Organisms","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"COLISTIMETHATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Central Nervous System Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Intra-abdominal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Skin, Bone, and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Complicated and Recurrent Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Serious Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3989564","indication_name":"Life-Threatening Gram-Negative Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"acyclovir-sodium","indication_name":"Neonatal Herpes Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ACYCLOVIR SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"cefuroxime-sodium","indication_name":"Lower Respiratory Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"cefuroxime-sodium","indication_name":"Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"cefuroxime-sodium","indication_name":"Skin and Skin-Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"cefuroxime-sodium","indication_name":"Bone and Joint Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"doxycycline","indication_name":"Respiratory tract infections caused by Mycoplasma pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Uncomplicated urethral, endocervical, or rectal infections in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Campylobacter fetus infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Infections caused by Escherichia coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Infections caused by Enterobacter aerogenes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Infections caused by Shigella species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Infections caused by Acinetobacter species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Respiratory tract infections caused by Haemophilus influenzae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Respiratory tract and urinary tract infections caused by Klebsiella species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Upper respiratory infections caused by Streptococcus pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"doxycycline","indication_name":"Infections caused by Clostridium species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mezlocillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEZLOCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Interleukin-8","drug_class":"mezlocillin","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"bacitracin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"BACITRACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"bacitracin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doxycyclin","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"gentamicin","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"erythromycin-ethyl-succinate","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eryped","generic_name":"Erythromycin ethyl succinate","company_name":"Arbor Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doripenem","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doribax","generic_name":"DORIPENEM","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"mavorixafor","indication_name":"infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolremdi","generic_name":"MAVORIXAFOR","company_name":"X4 Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"CXC Chemokine Receptor 4 Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Xolremdi blocks the CXC Chemokine Receptor 4 to treat WHIM syndrome."},{"drug_id":"gepotidacin","indication_name":"Uncomplicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blujepa","generic_name":"GEPOTIDACIN","company_name":"Glaxosmithkline","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":56,"revenue":null,"mechanism":"Blujepa works by inhibiting bacterial DNA polymerase, preventing the replication of bacterial DNA and ultimately leading to bacterial cell death."},{"drug_id":"tuberculin","indication_name":"M. tuberculosis infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aplisol","generic_name":"TUBERCULIN","company_name":"ENDO USA, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"Skin Test Antigen [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tonzonium","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin S","generic_name":"tonzonium","company_name":"Par Sterile Products","drug_phase":"marketed","molecular_target":"Insulin-degrading enzyme","drug_class":"tonzonium","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"amoxycillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxycillin","company_name":"King George's Medical University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"cefazolin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFAZOLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefazolin-sodium","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"Cefazolin Sodium","company_name":"GSK","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":60,"revenue":null,"mechanism":"Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"tobramycin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"tobramycin","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cefepime","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"cefpodoxime","indication_name":"Acute, uncomplicated ano-rectal infections in women","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime","indication_name":"Uncomplicated skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime","indication_name":"Uncomplicated urinary tract infections (cystitis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefpodoxime Proxetil","generic_name":"CEFPODOXIME","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Haemophilus Influenzae Type B Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Bacteroides Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Bacteroides Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulfadiazine","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sulfadiazine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"colistimethate-sodium","indication_name":"Klebsiella Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin M","generic_name":"COLISTIMETHATE SODIUM","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"colistimethate-sodium","indication_name":"Pseudomonas Aeruginosa Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin M","generic_name":"COLISTIMETHATE SODIUM","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftaroline","indication_name":"Acute bacterial skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftaroline Fosamil","generic_name":"CEFTAROLINE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins."},{"drug_id":"metronidazole","indication_name":"B. Fragilis Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"demeclocycline","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Demethylchlortetracycline","generic_name":"DEMECLOCYCLINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Tetracycline-class Antimicrobial","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"cefepime-hydrochloride","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"amoxicillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amoxil","generic_name":"amoxicillin","company_name":"Generic (originally Beecham/GSK)","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"Aminopenicillin (Beta-lactam antibiotic)","quality_score":56,"revenue":null,"mechanism":"Broad-spectrum aminopenicillin that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins."},{"drug_id":"cefepim","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"tobramycin-sulfate","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"colimycin","indication_name":"Klebsiella Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"colimycin","company_name":"Poitiers University Hospital","drug_phase":"phase_1","molecular_target":"Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"colimycin","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"colimycin","company_name":"Poitiers University Hospital","drug_phase":"phase_1","molecular_target":"Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"colimycin","indication_name":"Pseudomonas Aeruginosa Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"colimycin","company_name":"Poitiers University Hospital","drug_phase":"phase_1","molecular_target":"Melanocortin receptor 3, Melanocortin receptor 5, Epidermal growth factor receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"chlortetracycline","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aureomycin","generic_name":"CHLORTETRACYCLINE","company_name":"","drug_phase":"marketed","molecular_target":"Protein-arginine deiminase type-4","drug_class":"chlortetracycline","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Skin and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Uncomplicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"test-formulation-treatment-a","indication_name":"Uncomplicated Skin and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Test formulation (Treatment A)","generic_name":"test-formulation-treatment-a","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific enzyme","drug_class":"Enzyme inhibitor","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Synergy for Staphylococcal Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"meclocycline","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Meclan","generic_name":"MECLOCYCLINE","company_name":"Johnson And Johnson","drug_phase":"marketed","molecular_target":"","drug_class":"meclocycline","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Escherichia coli in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"atm-avi","indication_name":"Treatment of uncomplicated urinary tract infections (UTIs) caused by Klebsiella pneumoniae in patients who have a penicillin tolerance test result of >= 20 mcg/mL.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atm-Avi","generic_name":"atm-avi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"antibiotic","quality_score":37,"revenue":null,"mechanism":"ATM-AVI's mechanism of action is not specified on Wikipedia."},{"drug_id":"neomycin","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"neomycin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"piperacillin-and-tazobactam","indication_name":"Intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piperacillin And Tazobactam","generic_name":"Piperacillin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall; beta-lactamase enzyme","drug_class":"Penicillin-class antibacterial with beta-lactamase inhibitor","quality_score":64,"revenue":null,"mechanism":"Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor."},{"drug_id":"piperacillin-and-tazobactam","indication_name":"Skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piperacillin And Tazobactam","generic_name":"Piperacillin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall; beta-lactamase enzyme","drug_class":"Penicillin-class antibacterial with beta-lactamase inhibitor","quality_score":64,"revenue":null,"mechanism":"Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor."},{"drug_id":"piperacillin-and-tazobactam","indication_name":"Female pelvic infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Piperacillin And Tazobactam","generic_name":"Piperacillin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial cell wall; beta-lactamase enzyme","drug_class":"Penicillin-class antibacterial with beta-lactamase inhibitor","quality_score":64,"revenue":null,"mechanism":"Piperacillin and tazobactam is an antibacterial drug combining a penicillin with a beta-lactamase inhibitor."},{"drug_id":"colistin","indication_name":"Klebsiella Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin S","generic_name":"COLISTIN","company_name":"Par Sterile Products","drug_phase":"marketed","molecular_target":"Melanocortin receptor 3","drug_class":"colistin","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"colistin","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin S","generic_name":"COLISTIN","company_name":"Par Sterile Products","drug_phase":"marketed","molecular_target":"Melanocortin receptor 3","drug_class":"colistin","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"colistin","indication_name":"Pseudomonas Aeruginosa Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coly-Mycin S","generic_name":"COLISTIN","company_name":"Par Sterile Products","drug_phase":"marketed","molecular_target":"Melanocortin receptor 3","drug_class":"colistin","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxon","indication_name":"Haemophilus Influenzae Type B Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylene-blue","indication_name":"Diagnosis of certain types of infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methylthioninium Benzalkonium Chloride Hydrate","generic_name":"METHYLENE BLUE","company_name":"","drug_phase":"marketed","molecular_target":"Methemoglobin","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"cephalexin","indication_name":"Respiratory tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"cephalexin","indication_name":"Skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"cycloserine","indication_name":"Acute Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclorin","generic_name":"CYCLOSERINE","company_name":"Purdue Gmp","drug_phase":"marketed","molecular_target":"Glutamate receptor ionotropic, NMDA 2A","drug_class":"cycloserine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cephalexin","indication_name":"Genitourinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"polymyxin-b","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"polymyxin-b","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"amikacin","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"amikacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"ceftazidime","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"bicillin-c-r","indication_name":"Moderately severe to severe infections of the upper-respiratory tract","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bicillin C-R","generic_name":"Penicillin G Benzathine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cell-wall peptidoglycan biosynthesis","drug_class":"Beta-lactam antibiotic","quality_score":10,"revenue":null,"mechanism":"Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable."},{"drug_id":"bicillin-c-r","indication_name":"Skin and soft-tissue infections due to susceptible streptococci","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bicillin C-R","generic_name":"Penicillin G Benzathine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cell-wall peptidoglycan biosynthesis","drug_class":"Beta-lactam antibiotic","quality_score":10,"revenue":null,"mechanism":"Penicillin G inhibits bacterial cell-wall peptidoglycan biosynthesis, rendering the cell wall osmotically unstable."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"infections that are proven or strongly suspected to be caused by susceptible bacteria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Escherichia coli","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella pneumoniae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Citrobacter freundii","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterobacter cloacae","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Klebsiella oxytoca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecalis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"eravacycline","indication_name":"complicated intra-abdominal infections caused by Enterococcus faecium","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"cefalotin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cephalotin","generic_name":"cefalotin","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Solute carrier family 22 member 8","drug_class":"cefalotin","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"benzocaine","indication_name":"Tinea Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norcaine","generic_name":"BENZOCAINE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Complicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Uncomplicated urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"kanamycin","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kanacin","generic_name":"KANAMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Gap junction beta-2 protein","drug_class":"Aminoglycoside Antibacterial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tazicef","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"silvadene","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silvadene","generic_name":"Silver Sulfadiazine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"bacterial cell membrane and cell wall","drug_class":"sulfonamide antimicrobial","quality_score":10,"revenue":null,"mechanism":"Silver sulfadiazine acts on bacterial cell membrane and cell wall to produce bactericidal effect."},{"drug_id":"silvadene","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silvadene","generic_name":"Silver Sulfadiazine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"bacterial cell membrane and cell wall","drug_class":"sulfonamide antimicrobial","quality_score":10,"revenue":null,"mechanism":"Silver sulfadiazine acts on bacterial cell membrane and cell wall to produce bactericidal effect."},{"drug_id":"norfloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"mafenide","indication_name":"Burn Wound Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfamylon","generic_name":"MAFENIDE","company_name":"Rising","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 12","drug_class":"Methylated Sulfonamide Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"minocycline","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"minocycline","indication_name":"Ureaplasma Urealyticum Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"doxycycline","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Haemophilus Influenzae Type B Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"levofloxacin","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"cortisol","indication_name":"Mastoidectomy Cavity Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cephazolin","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephazolin","company_name":"HaEmek Medical Center, Israel","drug_phase":"phase_1","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cefazoline","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefazoline","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramocaine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"E. Coli Gynecological Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"B. Fragilis Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Complicated Urinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amoxicilli","indication_name":"Genitourinary Tract Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amoxicilli","company_name":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"minocyclin","indication_name":"Typhus Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"minocyclin","indication_name":"Ureaplasma Urealyticum Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cephalexin","indication_name":"Bone infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"omadacycline-tosylate","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuzyra","generic_name":"OMADACYCLINE TOSYLATE","company_name":"Paratek Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"benzoic-acid","indication_name":"Relief of local symptoms in lower urinary tract infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benzeneformic Acid","generic_name":"benzoic acid","company_name":"","drug_phase":"marketed","molecular_target":"Nicotinate phosphoribosyltransferase","drug_class":"Nitrogen Binding Agent [EPC]","quality_score":23,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"active","indication_name":"Respiratory Syncytial Virus Infections","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Active","generic_name":"active","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Sisunatovir","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rv521","indication_name":"Respiratory Syncytial Virus Infections","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RV521","generic_name":"rv521","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"RV521 drug in capsules","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":215,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT05919550","title":"Clozapine-associated Infection","phase":"","overall_status":"COMPLETED","enrollment_count":26815616,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06700941","title":"Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment","phase":"","overall_status":"COMPLETED","enrollment_count":8000000,"lead_sponsor_name":"Universidad Nacional de Colombia","has_results":false},{"nct_id":"NCT05353634","title":"Metagenomic Sequencing in Clinical Infectious Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":2022097,"lead_sponsor_name":"Liaocheng People's Hospital","has_results":false},{"nct_id":"NCT05321433","title":"Tobacco Use and the Risk of COVID-19 and Adverse Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":757585,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT02695173","title":"Complications of UTI in Patients on Dapagliflozin","phase":"","overall_status":"COMPLETED","enrollment_count":683380,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07094373","title":"Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data","phase":"","overall_status":"RECRUITING","enrollment_count":533000,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04110314","title":"Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2","phase":"NA","overall_status":"COMPLETED","enrollment_count":430636,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT06148532","title":"EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 2)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400000,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT00875641","title":"Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":390659,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05794191","title":"A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV","phase":"","overall_status":"COMPLETED","enrollment_count":350399,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04206241","title":"Assessing the Feasibility, Acceptability and Effects Of HIV Birth Testing In Maternity Settings In Zimbabwe","phase":"","overall_status":"COMPLETED","enrollment_count":278833,"lead_sponsor_name":"Elizabeth Glaser Pediatric AIDS Foundation","has_results":false},{"nct_id":"NCT05525494","title":"Patient Portal Flu Vaccine Reminders (5)","phase":"NA","overall_status":"COMPLETED","enrollment_count":262085,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT07334795","title":"Intermountain Stewardship in Community Outpatient Settings-Resources & Engagement-Pediatrics","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":259000,"lead_sponsor_name":"Intermountain Health Care, Inc.","has_results":false},{"nct_id":"NCT05535777","title":"Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)","phase":"NA","overall_status":"COMPLETED","enrollment_count":246295,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT05052190","title":"Patient Portal Flu Vaccine Reminders_RCT 4","phase":"NA","overall_status":"TERMINATED","enrollment_count":239567,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT03535558","title":"Fluoroquinolone Associated Disability","phase":"","overall_status":"COMPLETED","enrollment_count":239306,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07416266","title":"Lower Respiratory Tract Infections Managed in Primary Care in France","phase":"","overall_status":"COMPLETED","enrollment_count":230066,"lead_sponsor_name":"Hôpital Raymond Poincaré","has_results":false},{"nct_id":"NCT04533685","title":"Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3","phase":"NA","overall_status":"COMPLETED","enrollment_count":213773,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT05706064","title":"Survey of COVID-19 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT03666026","title":"Patient Portal - Flu Reminder Recall","phase":"NA","overall_status":"COMPLETED","enrollment_count":164205,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT06433700","title":"Risk of Revision Following Knee Arthroplasty in Bariatric Surgery Patients","phase":"","overall_status":"COMPLETED","enrollment_count":99965,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT03294473","title":"Centralized Reminder Recall - Flu RCT2","phase":"NA","overall_status":"COMPLETED","enrollment_count":70190,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05047900","title":"The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community","phase":"NA","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT03612297","title":"Selective Reporting of Antibiotic Susceptibility Test Results in Urinary Tract Infections in the Outpatient Setting","phase":"","overall_status":"UNKNOWN","enrollment_count":64000,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT00140673","title":"A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":63227,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06003192","title":"Screen Smart: Using Digital Health to Improve HIV Screening and Prevention","phase":"NA","overall_status":"RECRUITING","enrollment_count":63000,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT05770765","title":"Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"IRCCS Sacro Cuore Don Calabria di Negrar","has_results":false},{"nct_id":"NCT03871491","title":"Azithromycin-Prevention in Labor Use Study (A-PLUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":58747,"lead_sponsor_name":"NICHD Global Network for Women's and Children's Health","has_results":true},{"nct_id":"NCT01077856","title":"GARDASIL™ Vaccine Impact in Population Study (V501-033)","phase":"","overall_status":"COMPLETED","enrollment_count":54516,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT07145736","title":"Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":52000,"lead_sponsor_name":"Kirby Institute","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT04609423","title":"Cod Liver Oil for Covid-19 Prevention Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":47210,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT00861380","title":"Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":41188,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01686607","title":"Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents","phase":"","overall_status":"COMPLETED","enrollment_count":40110,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":false},{"nct_id":"NCT06758622","title":"Analysis on the Health of Newborns in Three Hospitals, 2008-2024","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40000,"lead_sponsor_name":"HOSPITAL GINECO OBSTETRICO ISIDRO AYORA","has_results":false},{"nct_id":"NCT04505098","title":"A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":39600,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT04615065","title":"Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT06268691","title":"Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating","phase":"NA","overall_status":"COMPLETED","enrollment_count":35000,"lead_sponsor_name":"Rocio Cardenas Sanchez","has_results":false},{"nct_id":"NCT03749434","title":"Understanding and Addressing Variations in HAIs After Durable Ventricular Assist Device Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":34958,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT00534638","title":"Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":34412,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06145724","title":"EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)","phase":"NA","overall_status":"RECRUITING","enrollment_count":33183,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT05712434","title":"Chlorhexidine to Prevent Catheter-related Urinary Tract Infection","phase":"NA","overall_status":"COMPLETED","enrollment_count":30994,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT01155193","title":"Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":30804,"lead_sponsor_name":"AbbVie (prior sponsor, Abbott)","has_results":true},{"nct_id":"NCT02946775","title":"Community Acquired Bacteremic Syndromes in Young Nigerian Children","phase":"","overall_status":"COMPLETED","enrollment_count":29146,"lead_sponsor_name":"University of Nebraska","has_results":false},{"nct_id":"NCT05407142","title":"An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":29000,"lead_sponsor_name":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","has_results":false},{"nct_id":"NCT07075029","title":"RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":28800,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04886596","title":"Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26675,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04666792","title":"PrEParing Family Planning Clinics to Streamline Integration of HIV Prevention Services for Young Women in Kenya","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":25457,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05349383","title":"Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities","phase":"","overall_status":"COMPLETED","enrollment_count":24618,"lead_sponsor_name":"Central South University","has_results":false},{"nct_id":"NCT00466947","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":23802,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}